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Amodiaquine retains efficacy against infection by chloroquine-resistant Plasmodium falciparum; however,
little information is available on its efficacy against infection by chloroquine-resistant Plasmodium vivax.
Patients presenting to a rural clinic with a pure P. vivax infection that recurred after recent antimalarial
treatment were retreated, this time with amodiaquine monotherapy, and the risk of further recurrence within
4 weeks was assessed. Of the 87 patients with pure P. vivax infection, 15 patients did not complete a full course
of treatment, 4 of whom were intolerant to treatment. In the 72 patients completing treatment, 91% (63 of 69)
had cleared their parasitemia within 48 h with no early treatment failure. Follow-up to day 28 or recurrent
parasitemia was achieved for 56 patients (78%). The cumulative incidence of treatment failure by day 28 was
22.8% (95% confidence interval, 7.3 to 38%). The in vitro sensitivity profile was determined for a separate set
of isolates from outpatients with pure P. vivax infection. The median 50% inhibitory concentration of amodi-
aquine was 11.3 nM (range, 0.37 to 95.8) and was correlated significantly with that of chloroquine (Spearman
rank correlation coefficient, 0.602; P < 0.001) Although amodiaquine results in a rapid clinical response, the
risk of recurrence by day 28 is unacceptably high, reducing its suitability as an alternative treatment of
infection by chloroquine-resistant P. vivax in this region.
Whereas chloroquine-resistant strains of Plasmodium falcip-
arum were documented in Cambodia and Brazil over 50 years
ago (8, 44), chloroquine resistant (CQR) Plasmodium vivax has
taken longer to emerge, with the first cases being described for
patients in Papua New Guinea and Papua, Indonesia, in 1989
(3, 34). Subsequent clinical studies have reported the presence
of CQR P. vivax across Asia (6, 21, 24, 26, 40) as well as South
America (12, 38). Despite this apparent threat to chloroquine-
based treatment practices, few studies have addressed suitable
alternative treatment regimens (2).
Amodiaquine is a 4-aminoquinoline which has been used
extensively to treat and prevent P. falciparum malaria since the
1940s. In 1990, amodiaquine prophylaxis was found to be as-
sociated with fatal hepatitis and agranulocytosis, which re-
sulted in the WHO recommendation that malaria control pro-
grams discontinue use of the drug (27, 43). However, a
subsequent systematic review found the drug to be safe and
well tolerated as a treatment (25), and although it is still con-
traindicated as a prophylactic agent, it is now widely used for
the treatment of infection by CQR P. falciparum, more re-
cently in combination with artesunate (1).
Studies of amodiaquine monotherapy for infection by P.
vivax are limited mostly to case reports (36), early prophylaxis
studies (41), and animal studies (11); there are also reports in
which the drug was used in combination with other antimalari-
als (15, 23). In southern Papua, Indonesia, where high-grade
drug resistance has emerged to infection by both P. falciparum
and P. vivax (33, 37), we have conducted a series of drug trials
to optimize treatment strategies (15, 32). In 2004 and 2005,
patients who failed treatment for recurrent P. vivax infections
were treated again, this time with amodiaquine monotherapy,
and their clinical responses were documented. In the present
study, we have pooled the clinical responses following amodi-
aquine monotherapy and have correlated them with the in
vitro responses of P. vivax to amodiaquine, including cross-
sensitivity to other drugs.
MATERIALS AND METHODS
Study site and design. This prospective open-label drug efficacy study of
amodiaquine monotherapy for P. vivax monoinfection was carried out at two
rural clinics west of Timika in southern Papua, Indonesia, between March 2004
and August 2005. This lowland region is partly forested, and Anopheles koliensis,
Anopheles farauti, and Anopheles punctulatus are responsible for unstable malaria
transmission (22, 28). The annual incidence of malaria in the region is 876 per
1,000 people per year, divided 60:40 between P. falciparum and P. vivax infections
(19). Local protocols recommend that all patients with patent parasitemia at any
level be given antimalarial therapy.
The present study is based on an in vivo antimalarial drug sensitivity protocol
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described previously (7). The results for 11 patients were presented previously as
part of a pilot study (33).
Patients. Patients who were previously enrolled in therapeutic trials taking
place at either clinic (32, 33) and who had any peripheral parasitemia with pure
P. vivax infection during follow-up were eligible for enrollment, irrespective of
parasite density or the presence of fever. Pregnant or lactating women and
children weighing less than 10 kg were excluded, as were patients with WHO
danger signs or signs of severity (42), a parasitemia level of 4%, or concomitant
disease requiring hospital admission.
Clinical laboratory examinations. A standardized data sheet, with a record of
demographic information, details of symptoms and their duration, and a history
of previous antimalarial medication, was completed for all patients enrolled in
the study. Clinical examination findings were documented, including the axillary
temperature. Venous blood was taken for blood film examination, hematocrit
determination, and white blood cell (WBC) count. Parasite counts were deter-
mined as the number of parasites per 200 WBCs by using Giemsa-stained thick
films, and peripheral parasitemia was assumed to be present with WBC counts of
7,300 l1. A thick smear was considered negative upon initial review if no
parasites were seen in 100 high-power fields. A thin smear was also examined to
confirm parasite species and was used for quantification if parasitemia was
greater than 200 per 200 WBCs. For cross-checking, 200 high-power fields were
examined before slides were considered negative. All slides were cross-checked
by a second experienced microscopist, and if readings were discordant, the slides
were read by a third microscopist and a consensus was reached.
Patients were examined daily thereafter until they became aparasitemic. At
each visit, a blood smear was taken and a symptom questionnaire was completed.
Patients were then seen weekly for 4 weeks. At each of these clinic appointments,
a full physical examination was performed, the symptom questionnaire was
completed, and blood was taken to check the parasite count and hemoglobin
level by using a battery-operated portable photometer (HemoCue Hb201;
Angelholm, Sweden). Blood spots on chromatography paper (Whatman BFC
180; Maidstone, United Kingdom) were also collected on day 0 and the day of
treatment failure.
Treatment. Amodiaquine was given at a total dose of 30 mg of base/kg of body
weight, divided into three daily doses, and participants were observed for 60 min
to exclude those with adverse reactions and to ensure that the medication was
not vomited. If vomiting occurred within 60 min, the whole dose was repeated
once. If vomiting occurred again within 60 min, the patient was withdrawn from
the study. For children, the tablet was crushed and placed in 5 ml of water, and
the correct dose was administered as a suspension.
Primaquine (15 mg of base/kg of body weight for 14 days) was administered on
day 28 of participation in the study if there was no evidence of glucose-6-
phosphate dehydrogenase deficiency. Patients with P. falciparum parasitemia
during follow-up were treated with unsupervised quinine (10 mg of salt/kg of
body weight for each dose, which was taken orally three times a day for 7 days)
plus doxycycline (100 mg twice daily) if they were 8 years of age and not
pregnant. When there were treatment failures for patients with P. vivax para-
sitemia, the patients were retreated using unsupervised quinine (10 mg of salt/kg
of body weight for each dose, which was taken orally three times a day for 7
days).
In vitro drug susceptibility assay. Previous studies have demonstrated that P.
vivax in vitro drug susceptibility cannot be ascertained reliably from patients with
a parasitemia level of less than 5,000 l1. Since most of the patients enrolled in
the in vivo study had low parasitemia levels or were young children who often
refused venipuncture, blood for in vitro drug susceptibility assays was collected
from hospital clinic outpatients who had parasitemia levels greater than 5,000
l1. Parasitemia levels of isolates tested ranged between 0.005% and 0.01%,
a level at which the inoculum size does not significantly affect the results of the
assay (14). Susceptibilities to chloroquine and amodiaquine were measured using
an identical protocol modified from the WHO microtest as described previously
(35). The in vitro activities of artesunate, mefloquine, and piperaquine were
tested for all isolates and that of lumefantrine was tested for a subset of 27
isolates. Incubation was stopped when parasites had matured to at least 40%
schizonts in the drug-free control well. A thick blood smear from each well was
Giemsa stained and examined microscopically. The number of schizonts per 200
asexual stage parasites was determined, and the result for each drug concentra-
tion was normalized to the control well. The dose response data were analyzed
using nonlinear regression analysis (WinNonlin 4.1; Pharsight Corporation) to
obtain the IC50s.
The susceptibilities of 53 samples were published in a previous study of the
confounding factors of assay conditions on the in vitro response (35). That study
documented a significant stage specificity of drug activity, with isolates predom-
inantly at the trophozoite stage being less susceptible to drug activity; for this
reason, the analysis of in vitro drug susceptibilities in the present study was
restricted to those isolates that had predominantly ring stages initially (ring-to-
trophozoite ratio greater than 1).
Molecular analysis. In patients with recurrent P. vivax infections, either alone
or mixed, genomic DNA from blood spots was extracted using a QIAamp DNA
mini kit (Qiagen, Doncaster, Australia). Genotypes in paired isolates were de-
termined by restriction fragment analyses of the pvmsp3 locus and size poly-
morphisms in pvmsp1 fragments F1 and F3, as described previously (9, 17).
Statistical analysis. Data were double entered and validated using EpiData
3.02 software (EpiData Association, Odense, Denmark), and analyses were per-
formed using SPSS for Windows version 14 (SPSS, Inc., Chicago, IL). The
Mann-Whitney U test was used for nonparametric comparisons, and Student’s t
test or one-way analysis of variance was used for parametric comparisons. Pro-
portions were examined using 2 with Yates’ correction or by Fisher’s exact test.
Efficacy endpoints were assessed by survival analysis, in which the cumulative
risk of failure was calculated by the Kaplan Meier product limit formula. Data
for patients who were lost to follow-up or who presented with a peripheral
parasitemia without P. vivax were censored from analysis. Those patients with
recurrent vomiting or adverse drug effects which required early termination of
treatment and the administration of rescue therapy were excluded from the
primary analysis but included in a secondary conservative analysis in which they
were regarded as therapeutic failures.
Ethics. The study was approved by the Ethics Committee of the National
Institute of Health Research and Development, Indonesian Ministry of Health
(Jakarta, Indonesia), and the Ethics Committee of Menzies School of Health
Research (Darwin, Australia). Written informed consent was obtained from
adult patients and parents of enrolled children. The trial was registered at the
NIH clinical trials website (http://www.clinicaltrials.gov/ct) under identifier code
NCT00157859.
RESULTS
Between April 2004 and July 2005, 95 patients with P. vivax
infection were enrolled in the in vivo study. The day after
enrollment, the blood films were rechecked, and slides from
eight patients were found not to contain pure P. vivax; these
patients were excluded from further analysis (Fig. 1). The
baseline characteristics of the remaining 87 patients in the
evaluable population are presented in Table 1.
The active case detection was reflected in the low parasite
density upon admission (geometric mean, 672 l1; 95% con-
fidence interval [CI], 455 to 993) with only 51% (42 of 82)
being symptomatic (fever or history of fever in the preceding
24 h).
Overall 63% of patients (54 of 87) had been treated previ-
ously for P. vivax infection, either alone (39 patients) or mixed
with P. falciparum (15 patients) with the remaining patients
previously infected with pure P. falciparum (25 patients), Plas-
modium malariae (6 patients), or Plasmodium ovale (2 pa-
tients). The prior treatment was administered for a median of
29 days (range, 4 to 47 days), with 54 patients receiving treat-
ment with artemether-lumefantrine, 19 with chloroquine, 10
with DHA-piperaquine, and 4 with quinine.
Tolerability. In total, 4.6% of patients (4 of 87) vomited
their medication within 30 min of administration. Although
this proportion was higher for children under 5 years old (11%;
2 of 18) than for older children and adults (2.9%; 2 of 69), it
did not reach statistical significance (P 0.19). Two patients (a
child and an adult) were unable to tolerate their medication
because of recurrent vomiting. A further two patients were
withdrawn by the attending physician due to possible drug
reactions: a 2-year-old child experienced urticaria after the first
dose, and a 4-year-old child developed acute asthma on day 2.
These four patients were withdrawn from the study and treated
with oral quinine; they made a full recovery. A further 11
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patients failed to return to the clinic to complete their course
of medication.
Of the 72 patients who received a full treatment course, the
mean dose of amodiaquine given was 31.0 mg/kg (95% CI, 29.7
to 32.2; range, 17.7 to 65.6). Follow-up to day 28 or to the day
of treatment failure in these patients was achieved for 78% of
patients (56 of 72).
Therapeutic response. Overall, 52% of patients (36 of 69)
cleared their peripheral parasitemia within 24 h, with a median
parasite reduction ratio of 8.7 (range, 0.3 to 330). By 48 h, 91%
(63 of 69) were aparasitemic, and 73% of those patients ini-
tially presenting with symptoms (19 of 26) were asymptomatic.
There were no early parasitological failures. In total, 25% of
patients (20 of 81) had P. vivax gametocytes present on the
admission blood film. By day 7, none of the patients with P.
vivax infections had gametocytes present upon blood film ex-
amination, and no gametocytes were recorded on subsequent
blood films during follow-up. In total, 41% of patients (30 of
74) were anemic on admission (hemoglobin 	10 g/dl). By day
7, this proportion had fallen to 30% (6 of 20 patients), and by
day 28, none of the 9 patients tested were anemic.
Twelve patients had a recurrence of malaria during follow-
up, seven with P. vivax, four with P. falciparum, and one with a
mixed infection of both species. At the time of recurrence,
42% of these patients (5 of 12) were symptomatic, reporting
malaise, fever, or a history of fever. Of those patients complet-
ing treatment, the cumulative risk of recurrence of P. vivax by
day 28 (either alone or mixed) was 22.8% (95% CI, 7.3 to 38),
with all recurrences occurring on or after day 27. In the evalu-
able population, patients who had incomplete treatment
courses or who required early rescue treatment were assumed
to be treatment failures; thus, the cumulative risk of treatment
failure rose to 39% (95% CI, 24 to 53).
Molecular analysis of recurrent infections. DNA was avail-
able from both pre- and posttreatment isolates from five of the
eight patients with P. vivax infection who failed treatment.
PCR amplification of these paired isolates was successful for
four of these pairs, with recurrence of the same genotype
present in three cases.
In vitro susceptibility. Between March 2004 and August
2008, 137 isolates with the initial majority at the ring stage
(ring-to-trophozoite ratio greater than 1) were subjected to in
vitro susceptibility testing, from which reliable data could be
derived for 103 (75%). None of these isolates came from pa-
tients for whom the in vivo response was also documented. The
median 50% inhibitory concentration (IC50) for amodiaquine
was 11.3 nM (range, 0.37 to 95.8), compared to 52.7 nM
(range, 4.6 to 3,506) for chloroquine, 1.29 nM (range, 0.043 to
13.6) for artesunate, 16.0 nM (range, 4.8 to 228.6) for lume-
fantrine, 8.2 nM (range, 0.81 to 137.9) for mefloquine, and 17.5
nM (range, 1.8 to 119.9) for piperaquine. The IC50s of amo-
diaquine were correlated with those for chloroquine (Spear-
man rank correlation coefficient [rs]  0.602, P 	 0.001) (Fig.
2), artesunate (rs  0.577, P 	 0.001), mefloquine (rs  0.636,
P 	 0.001), and piperaquine (rs  0.658, P 	 0.001) but not
with that of lumefantrine (n 27). In total, 34% of the isolates
(33 of 98) had chloroquine IC50s greater than 100 nM, whereas
the maximum reported IC50 of amodiaquine was 95.8 nM.
TABLE 1. Baseline characteristics of patients in the
evaluable population
Patient parameter
Result (no. of patients
with indicated
characteristic/total
no. of patients)
No. in evaluable population ..........................................87
Parasitemia levela 
95% CI ......................................672 
455–993
Gametocyte carriage (%) ..........................................25 (20/81)
Male (%) .........................................................................55 (48/87)
Age (yr)
Median 
range............................................................13 
2–53
	5 (%).........................................................................21 (18/87)
5–14 (%) ......................................................................37 (32/87)
14 (%).......................................................................43 (37/87)
Temp 37.5°C (%) ........................................................8.5 (7/82)
Symptomatic (%)............................................................51 (42/83)
Hemoglobinb 
SD ..........................................................10.5 
1.7
Anemiac (%) ...................................................................41 (30/74)
Splenomegaly (%) ..........................................................64 (52/81)
a Geometric mean; l1.
b Mean; g/dl.
c Hemoglobin 	10 g/dl.
FIG. 1. Trial profile of patients treated with amodiaquine.
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DISCUSSION
In Asia and South America, P. vivax is a major and under-
appreciated cause of morbidity (29). Chloroquine treatment
remains the mainstay for vivax malaria in countries where it is
endemic, but it is being increasingly undermined by the emer-
gence and spread of CQR. The evidence on which to base
alternative treatment strategies is limited (2). Amodiaquine, a
4-aminoquinoline, has been shown to retain activity against
CQR strains of P. falciparum, although with various levels of
efficacy (25), and it has been incorporated into national control
programs, usually in combination with artesunate (1). The
efficacy of amodiaquine against CQR strains of P. vivax has
been less studied. Two clinical trials of amodiaquine in com-
bination with artesunate (in Papua, Indonesia) or sulfadoxine-
pyrimethamine (in Papua New Guinea) revealed recurrence
rates of 12 to 26% by day 28 (15, 23). Both studies were
conducted in areas with highly CQR P. vivax. CQR P. vivax was
first documented in Papua, Indonesia, in 1991 (3), but over the
ensuing decade, recurrence rates in the north of the province
have risen to almost 95% by day 28 (39). We have reported
high-grade resistance in patients in Timika, southern Papua,
Indonesia, with 29% of patients failing treatment within 1
week of chloroquine monotherapy and 16% showing signs of
early treatment failure (33).
In the present study, we have pooled our experience of
patients treated with amodiaquine monotherapy to assess its in
vitro and in vivo efficacy against infection by CQR P. vivax.
Amodiaquine was reasonably well tolerated, although almost
one-fifth of patients failed to complete treatment, either be-
cause of nausea and vomiting (4.5%) or noncompliance (13%).
In contrast to the high risk of early treatment failure following
chloroquine monotherapy, there were no high-grade failures
following amodiaquine monotherapy, and by 48 h, the periph-
eral parasitemia in 91% of patients had cleared. Despite this
apparent early treatment success, it is noteworthy that at the
start of treatment many of the enrolled patients had relatively
low parasitemia levels, which had been detected actively, and
half of whom were asymptomatic. In those patients completing
treatment, the cumulative incidence of recurrence of P. vivax
infection at day 28 was 23%. Clinical trials with P. vivax are
confounded by both the occurrence of reinfections and re-
lapses from liver stages (hypnozoites) (5). Whereas parasite
genotyping has proved useful for the interpretation of clinical
trials in P. falciparum, its utility in discriminating relapse, re-
infection, and recrudescence in P. vivax is limited (10, 18).
In our study, four recurrent isolates could be genotyped at
three loci; three of the isolates were the same as the isolate
present upon admission of the patient. Assuming that these
three isolates and the four indeterminate isolates were recru-
descent infection, the cumulative risk of failure risk could be
adjusted to 21%. An alternative and equally plausible expla-
nation is that these recurrent infections represent relapses
from hypnozoites from the same genotype (10, 18). In Papua,
P. vivax relapses occur 3 to 6 weeks apart in up to 70% of
patients (4). The long terminal elimination of chloroquine
ensures that recurrent infections occurring within 28 days of
supervised administration will grow in the presence of chloro-
quine concentrations normally inhibitory to sensitive parasites
and thus can be considered resistant (2). Desethylamodia-
quine, the active metabolite of amodiaquine, has a terminal
elimination half-life of approximately 9 to 18 days (16, 31),
significantly shorter than the 20 to 60 days reported for chlo-
roquine (13). Its ability to suppress the first relapse is therefore
likely to be correspondingly diminished compared to that of
chloroquine. We observed no recurrences of infection by P.
vivax before day 27. Interestingly, the cumulative risk of recur-
rence by day 28 was similar to that observed in a subsequent
study of pure P. vivax infection treated with amodiaquine plus
3 days with artesunate (23% and 26%, respectively) (15), sug-
gesting that the recurrent P. vivax infections represent predict-
able relapses rather than recrudescence of resistant isolates.
Venous sampling of drug concentrations at the time of recur-
rence would have helped to define resistant isolates but,
unfortunately, was not available for our study.
Currently, the only available strategy for preventing the re-
lapse of infection by P. vivax is a prolonged course of prima-
quine (4), although shorter courses with high doses hold prom-
ise (20). Local guidelines advocate the administration of 14
days of primaquine, although in the present study, this was
delayed until the end of the study. Earlier administration might
FIG. 2. In vitro correlation of isolates tested for both amodiaquine and chloroquine (n  98, rs  602; P 	 0.001).
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have decreased the observed recurrence rate; however, in prac-
tice, long courses of unsupervised therapy are rarely adhered
to and thus are likely to be of limited benefit. Treatment
regimens which lead to the retention of a prolonged antima-
larial suppression, such as piperaquine, mefloquine, and, in
sensitive areas, chloroquine, provide the only practical means
currently available for delaying the timing of clinical illness
from relapses in areas of endemicity (32). Importantly, there
were no early failures following amodiaquine treatment, as
were frequently observed with chloroquine monotherapy (33).
Within 24 h, the median parasite reduction ratio was 8, similar
to that observed following mefloquine or halofantrine treat-
ment of infection by P. vivax in Thailand, but significantly less
than that of chloroquine-sensitive isolates, which had a median
of 36 (30). The in vitro susceptibility profiles of the Papuan
isolates highlight the low IC50s for amodiaquine but showed
appreciable cross-resistance with chloroquine, mefloquine, ar-
tesunate, and piperaquine. Hence, although amodiaquine re-
tains substantial efficacy against infection by CQR strains of P.
vivax, it is vulnerable to cross-resistance in this region. Despite
the strong correlation between amodiaquine and chloroquine
susceptibilities, none of the isolates tested had an IC50 greater
than 100 nM, even though one-third of the same isolates had
chloroquine IC50s above this level.
In summary, amodiaquine monotherapy retained significant
clinical and in vitro efficacy against P. vivax, although recur-
rence rates within 28 days were unacceptably high. Since com-
bination therapy with artesunate does not improve the clinical
outcome at day 28, and practical strategies for reducing the
relapses are not immediately forthcoming, the utility of amo-
diaquine as an alternative to chloroquine in areas of emerging
antimalarial drug resistance remains tenuous.
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